Exelixis (EXEL) News Today

Exelixis, Inc. (NASDAQ: EXEL) shares have moved higher amid a wave of bullish analyst commentary, unusual call-option activity, and positive trial and sales updates.

• Positive Sentiment: Zacks includes EXEL among five top-ranked stocks expected to beat bottom-line estimates in the upcoming quarter. Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
• Positive Sentiment: Seeking Alpha upgrades EXEL after admitting its prior cautious stance was too conservative. Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)
• Positive Sentiment: Reports surface of unusually large call-option trades in EXEL, indicating bullish positioning. Exelixis Target of Unusually Large Options Trading (NASDAQ:EXEL)
• Positive Sentiment: MarketBeat notes a 56% jump in daily call-option volume on EXEL, pointing to growing investor optimism. Stock Traders Buy High Volume of Call Options on Exelixis (NASDAQ:EXEL)
• Positive Sentiment: Zacks highlights EXEL as a top long-term growth stock based on its Style Scores. Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
• Positive Sentiment: Zacks reports EXEL shares have surged over 35% in three months, fueled by strong Cabometyx sales and positive trial results for zanzalintinib. Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
• Neutral Sentiment: Amid fears of NCI budget cuts, emerging oncology names including EXEL are attracting renewed investor attention. Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
• Neutral Sentiment: Royal Bank of Canada reaffirmed a sector-perform rating on EXEL and raised its price target to $50 from $45. Briefing.com Automated Import Finviz
• Negative Sentiment: Royal Bank of Canada downgraded EXEL from outperform to sector-perform despite lifting the price objective to $50. Exelixis (NASDAQ:EXEL) Downgraded by Royal Bank Of Canada to "Sector Perform"